• INDIGO Biosciences Expands Portfolio to Include Cannabinoid Type 1 Receptor

    3 monthes ago - By Indigo Biosciences

    CB1R Assay Implicated in Cancer Therapies and Neurological Disorders State College, PA - INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust testing portfolio to include a new Cannabinoid Type 1 Receptor assay, primarily used in developing cancer side effect-related treatments and implicated in the development
    Read more ...